Patents by Inventor Andreas WEIGERT

Andreas WEIGERT has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibody inhibitors of IL-38 and methods of use thereof for treating or reducing the likelihood of cancer in a subject
    Patent number: 11427630
    Abstract: An inhibitor of IL-38 is useful for treating and/or preventing cancer in a subject. A pharmaceutical composition can include an inhibitor of IL-38. A method for treating and/or preventing cancer is carried out by administering an inhibitor of IL-38 in a therapeutically effective amount. Another method is useful for identifying an inhibitor of IL-38.
    Type: Grant
    Filed: May 7, 2018
    Date of Patent: August 30, 2022
    Assignee: FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V.
    Inventors: Andreas Weigert, Javier Mora, Bernhard Brüne, Mateusz Putyrski, Michael John Parnham, Andreas Ernst
  • N-TERMINALLY TRUNCATED INTERLEUKIN-38
    Publication number: 20200277349
    Abstract: The present invention pertains to an N-terminally truncated interleukin (IL)-38 protein, or functional variants thereof, as well as to nucleic acids and vectors encoding the truncated IL-38 peptide and recombinant cells comprising these nucleic acids or vectors. The invention shows that IL-38 is N-terminally processed and that the truncated version of the cytokine acts as an antagonist of immune activation in macrophages. This indicates a use of the truncated cytokine in the treatment and prevention of autoimmune disorders. The invention further provides pharmaceutical compositions comprising the truncated IL-38 protein, and method for screening modulators of the function of truncated IL-38.
    Type: Application
    Filed: March 2, 2020
    Publication date: September 3, 2020
    Inventors: Andreas WEIGERT, Javier MORA, Bernhard BRUNE, Christina DILLMANN, Michael John PARNHAM, Gerd GEISSLINGER
  • INHIBITORS OF IL-38 FOR USE IN TREATING AND/OR PREVENTING CANCER IN A SUBJECT
    Publication number: 20200165334
    Abstract: An inhibitor of IL-38 is useful for treating and/or preventing cancer in a subject. A pharmaceutical composition can include an inhibitor of IL-38. A method for treating and/or preventing cancer is carried out by administering an inhibitor of IL-38 in a therapeutically effective amount. Another method is useful for identifying an inhibitor of IL-38.
    Type: Application
    Filed: May 7, 2018
    Publication date: May 28, 2020
    Inventors: Andreas WEIGERT, Javier MORA, Bernhard BRÜNE, Mateusz PUTYRSKI, Michael John PARNHAM, Andreas ERNST
  • N-terminally truncated interleukin-38
    Patent number: 10618946
    Abstract: The present invention pertains to an N-terminally truncated interleukin (IL)-38 protein, or functional variants thereof, as well as to nucleic acids and vectors encoding the truncated IL-38 peptide and recombinant cells comprising these nucleic acids or vectors. The invention shows that IL-38 is N-terminally processed and that the truncated version of the cytokine acts as an antagonist of immune activation in macrophages. This indicates a use of the truncated cytokine in the treatment and prevention of autoimmune disorders. The invention further provides pharmaceutical compositions comprising the truncated IL-38 protein, and method for screening modulators of the function of truncated IL-38.
    Type: Grant
    Filed: July 14, 2015
    Date of Patent: April 14, 2020
    Assignee: FRAUNHOFER-GESELLSCHAFT ZUR FÖRDERUNG DER ANGEWANDTEN FORSCHUNG E.V.
    Inventors: Andreas Weigert, Javier Mora, Bernhard Brune, Christina Dillmann, Michael John Parnham, Gerd Geisslinger
  • N-TERMINALLY TRUNCATED INTERLEUKIN-38
    Publication number: 20170218039
    Abstract: The present invention pertains to an N-terminally truncated interleukin (IL)-38 protein, or functional variants thereof, as well as to nucleic acids and vectors encoding the truncated IL-38 peptide and recombinant cells comprising these nucleic acids or vectors. The invention shows that IL-38 is N-terminally processed and that the truncated version of the cytokine acts as an antagonist of immune activation in macrophages. This indicates a use of the truncated cytokine in the treatment and prevention of autoimmune disorders. The invention further provides pharmaceutical compositions comprising the truncated IL-38 protein, and method for screening modulators of the function of truncated IL-38.
    Type: Application
    Filed: July 14, 2015
    Publication date: August 3, 2017
    Inventors: Andreas WEIGERT, Javier MORA, Bernhard BRÜNE, Christina DILLMANN, Michael John PARNHAM, Gerd GEISSLINGER